Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.41 |
| ▸ | RARG | P13631 | 6/20 | 0.41 |
| ▸ | RARA | P10276 | 5/20 | 0.41 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 5/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749716 | 0.99 | PLA2G2D (0.41) | RARBRARGRARAPLA2G2DPTPN11 | |
| SCHEMBL6751407 | 0.87 | PDK2 (0.39) | PLA2G2DPPARD | |
| SCHEMBL6751669 | 0.86 | PDK2 (0.39) | PLA2G2DPPARD | |
| SCHEMBL4868253 | 0.86 | APP (0.33) | — | |
| SCHEMBL6749810 | 0.81 | LMNA (0.51) | PLA2G2DPPARDMRGPRX4 | |
| SCHEMBL7528750 | 0.80 | HDAC1 (0.41) | RARBRARAPTPN11 | |
| SCHEMBL9406144 | 0.80 | PTPN11 (0.60) | RARBPLA2G2DPTPN11 | |
| SCHEMBL4862292 | 0.79 | RARB (0.38) | RARBPLA2G2DPTPN11 | |
| SCHEMBL4862352 | 0.79 | RARB (0.38) | RARBPLA2G2DPTPN11 | |
| SCHEMBL4872013 | 0.79 | RARB (0.59) | RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7083832-B2 | Partially fluorinated liquid crystal material | DISPLAYTECH, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-6703082-B1 | VARIOUS NAPHTHALENE-CONTAINING LIQUID CRYSTALS | DISPLAYTECH, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20030017278-A1 | Partially fluorinated liquid crystal material | CITIZEN FINETECH MIYOTA CO., LTD. (JP) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017278-A1 | Partially fluorinated liquid crystal material | LEF1, SETDB1, INF2 | RARB 3093/4885RARG 2932/4885RARA 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.